Elizabeth Mily, the lead acquisition and deal negotiator at Bristol Myers Squibb, is leaving the Big Pharma, a spokesperson confirmed to Endpoints News on Friday morning. Since joining Bristol Myers in the spring of 2020 […]
SEOUL, South Korea and LONG BEACH, Calif., Dec. 7, 2023 /PRNewswire/ — Medit (www.medit.com), a leading provider of 3D intraoral scanners and digital dentistry solution, proudly announces significant updates to its Medit Link software. These […]
CatalYm’s solid tumor candidate, which targets a protein previously explored in obesity, has boosted responses in combination with an immune checkpoint inhibitor in an early-stage trial. The results pave the way for the next stage […]
CAMARILLO, Calif., Dec. 6, 2023 /PRNewswire/ — SaniSure, a global player in single-use bioprocessing solutions (drug substance and drug product form & fill) and cell & gene therapy is proud to announce that it has […]
Plus, news about Eligo Bioscience, EyePoint, Xenon and Merus: AbbVie signs AI pact: For $30 million upfront, the pharma is partnering with BigHat Biosciences to develop new antibodies in oncology and neuroscience. It’s the second […]
LOS ANGELES, Dec. 5, 2023 /PRNewswire/ — The Prostate Cancer Foundation (PCF) and Bayer today announced three 2023 Bayer-PCF Health Equity Research Challenge Awards totaling $600,000. The awards will support novel health equity research projects […]
AstraZeneca is joining forces with Absci in a deal worth up to $247 million focused on using AI to conduct large-scale protein analysis to design a new antibody-based drug candidate for cancer. The $247 million […]
Seismic Therapeutic has raised $121 million in a Series B, about 20% larger than it had originally sought, to enter the clinic with two biologics created using its machine learning tools, it said Monday morning. […]
Prem Rawat presented a lecture titled “Understanding the Value of Life: Know Thyself” to an audience of 375,603 people, setting a new world record for the “largest attendance at a single lecture.” This is the […]
Samsung Bioepis reached a deal this week that would allow its Stelara biosimilar hopeful to launch in February 2025, adding to mounting competition against Johnson & Johnson’s anti-inflammatory blockbuster. However, it’s unlikely the candidate — […]
© 2023 Biotech Networks, LLC
